BIIB monthly performance report
Explore BIIB's monthly returns, drawdown, and seasonality trends — updated every month.
BIIB monthly report
—
Key takeaways
- Biogen (BIIB) closed November 2026 at $253.40, down 0.09% for the month and +53.83% over the trailing 12 months.
- Year-to-date, BIIB is +43.99%, outperforming the S&P 500 which has returned +10.62% YTD.
- The stock is trading +23.57% versus its 200-day moving average ($205.07), a bullish technical signal.
- Over the past three years, BIIB has underperformed the S&P 500 by −57.53%, with a relative strength index reading of 66.4.
- Win rate over the trailing 39 months stands at 43.6% — 17 positive months versus 22 negative months.
Biogen ended November 2026 at $253.40, posting a monthly return of −0.09%. The S&P 500 returned −0.18% over the same window, leaving relative performance at +0.09%.
The current quarter stands at +12.18% (Q4 2026 (QTD)), while medium-term trend remains constructive: price is +23.57% versus the 200-day moving average ($205.07).
Year-to-date, BIIB is +43.99% against SPY +10.62%, a gap of +33.36%. The stock is currently −2.91% below its 52-week high, with maximum 3-year drawdown at −57.65%.
| Period | BIIB | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +1.17% | −0.36% | +1.53% |
| 1 Week | +2.03% | +2.59% | −0.56% |
| 1 Month | −0.09% | −0.18% | +0.09% |
| 3 Months | +21.16% | −2.37% | +23.53% |
| 6 Months | +32.41% | +0.83% | +31.58% |
| YTD | +43.99% | +10.62% | +33.36% |
| 12 Months | +53.83% | +12.25% | +41.58% |
| 3 Years | +13.84% | +71.37% | −57.53% |
| Rank | Month | Return |
|---|---|---|
| #1 | Nov 2025 | +18.03% |
| #2 | Oct 2026 | +12.28% |
| #3 | Dec 2023 | +10.55% |
| #4 | Jun 2026 | +10.23% |
| #5 | Oct 2025 | +10.13% |
| Rank | Month | Return |
|---|---|---|
| #1 | Feb 2024 | −12.03% |
| #2 | Apr 2025 | −11.52% |
| #3 | Oct 2024 | −10.24% |
| #4 | Jul 2024 | −8.03% |
| #5 | Nov 2024 | −7.68% |
| Quarter | Return |
|---|---|
| Q3 2025 | +11.54% |
| Q4 2025 | +25.64% |
| Q1 2026 | +4.17% |
| Q2 2026 | +17.85% |
| Q3 2026 | +4.55% |
| Q4 2026 (QTD) | +12.18% |
| Year | Return |
|---|---|
| 2023 | −6.55% |
| 2024 | −40.91% |
| 2025 | +15.09% |
| 2026 | +43.99% |
| Metric | Value |
|---|---|
| 52-Week High | $261.00 (2026-11-09) |
| 52-Week Low | $158.05 (2025-11-12) |
| Current Price | $253.40 |
| 200-Day Moving Average | $205.07 |
| Price vs 200DMA | +23.57% |
| 3-Year Maximum Drawdown | −57.65% (2025-04-10) |
| Current Drawdown from 52W High | −2.91% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 66.4 |
| 3-Year Excess Return vs S&P 500 | −57.53% |
| RS Peak | 112 (Jan 2024) |
| RS Trough | 38.6 (Jul 2025) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was BIIB's return for this report period?
BIIB returned −0.09% in the latest monthly window ending 2026-11-13.
Has BIIB outperformed SPY year to date?
YTD BIIB: +43.99% vs SPY: +10.62%.
What is BIIB's 12-month return?
+53.83% over the trailing 12 months.
Is BIIB above or below its 200-day moving average?
Price is +23.57% versus 200DMA ($205.07).
What is the maximum drawdown in the 3-year window?
−57.65% on 2025-04-10.